Cubist Systematic Strategies LLC Acquires New Holdings in Keryx Biopharmaceuticals, Inc. (KERX)

Cubist Systematic Strategies LLC acquired a new stake in shares of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,342 shares of the biopharmaceutical company’s stock, valued at approximately $183,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Principal Financial Group Inc. increased its position in shares of Keryx Biopharmaceuticals by 4.2% during the second quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 590 shares during the period. Jane Street Group LLC bought a new stake in shares of Keryx Biopharmaceuticals during the first quarter valued at about $141,000. Legal & General Group Plc increased its position in shares of Keryx Biopharmaceuticals by 1.2% during the first quarter. Legal & General Group Plc now owns 25,985 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 300 shares during the period. Stifel Financial Corp increased its position in shares of Keryx Biopharmaceuticals by 11.5% during the first quarter. Stifel Financial Corp now owns 33,736 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 3,478 shares during the period. Finally, Lincoln Capital Corp increased its position in shares of Keryx Biopharmaceuticals by 20.5% during the second quarter. Lincoln Capital Corp now owns 36,500 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 6,200 shares during the period. 65.20% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This story was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.com-unik.info/2017/11/05/cubist-systematic-strategies-llc-acquires-new-holdings-in-keryx-biopharmaceuticals-inc-kerx.html.

Shares of Keryx Biopharmaceuticals, Inc. (NASDAQ KERX) opened at $6.37 on Friday. The company has a current ratio of 5.76, a quick ratio of 5.16 and a debt-to-equity ratio of 4.88.

Several research analysts recently weighed in on the stock. Zacks Investment Research cut shares of Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, September 14th. ValuEngine upgraded shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. BidaskClub cut shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Cowen and Company reiterated a “market perform” rating on shares of Keryx Biopharmaceuticals in a research report on Tuesday, July 25th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $7.00 price target (up from $4.00) on shares of Keryx Biopharmaceuticals in a research report on Tuesday, July 25th. One analyst has rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the company. Keryx Biopharmaceuticals presently has a consensus rating of “Hold” and an average price target of $7.48.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Want to see what other hedge funds are holding KERX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX).

Institutional Ownership by Quarter for Keryx Biopharmaceuticals (NASDAQ:KERX)

What are top analysts saying about Keryx Biopharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Keryx Biopharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit